Breaking News Instant updates and real-time market news.

ECYT

Endocyte

$4.96

0.14 (2.90%)

, PGNX

Progenics

$5.52

-0.07 (-1.25%)

13:25
11/27/17
11/27
13:25
11/27/17
13:25

Wedbush biotech analyst holds an analyst/industry conference call

Biotech Analyst Nierengarten, along with Key Opinion Leader Michael Morris, MD and Medical Oncologist at Memorial Sloan Kettering, provide an update on radiopharmaceutical oncology on an Analyst/Industry conference call to be held on November 27 at 2 pm.

ECYT

Endocyte

$4.96

0.14 (2.90%)

PGNX

Progenics

$5.52

-0.07 (-1.25%)

  • 27

    Nov

ECYT Endocyte
$4.96

0.14 (2.90%)

10/03/17
WEDB
10/03/17
UPGRADE
WEDB
Outperform
Endocyte upgraded to Outperform from Neutral at Wedbush
Wedbush analyst David Nierengarten upgraded Endocyte to Buy and increased its price target to $7 from $2 based on the attractive PSMA-617 opportunity and cheap valuation, despite share strength yesterday. The analyst sees potential peak sales of $1B and said it could have a broader opportunity and fewer hurdles in scaling up relative to Xofigo.
06/05/17
06/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sector Weight from Overweight at Pacific Crest with analyst Andy Hargreaves saying upside from the launch of iPhone 8 is already reflected in the shares. An "extremely strong iPhone 8 cycle" is being priced into the stock while little weight is being given to gross margins, supply issues, or the likelihood for declines beyond the iPhone 8, Hargreaves tells investors in a research note. 2. Perrigo (PRGO) downgraded to Underperform from Sector Perform at RBC Capital with analyst Randall Stanicky saying the growth rate of the company's U.S. consumer business "has structurally re-rated lower" amid pricing headwinds and share losses. 3. Endocyte (ECYT) downgraded to Neutral from Outperform at Wedbush and to Market Perform from Outperform at Cowen. 4. Affiliated Managers (AMG) was downgraded to Neutral from Buy at Citi while Federated Investors (FII) was downgraded to Sell from Neutral. 5. Veeva (VEEV) downgraded to Equal Weight from Overweight at Morgan Stanley with the firm's analyst saying the 60%+ move in shares year-to-date captures much of the near-term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/05/17
WEDB
06/05/17
DOWNGRADE
WEDB
Neutral
Endocyte downgraded on clinical data, pipeline changes at Wedbush
As noted earlier, Wedbush downgraded Endocyte to Neutral from Outperform. Analyst David Nierengarten downgraded the stock after the company reported that the level of activity observed in trials did not support further development of its EC1456 or its EC1169 in taxane-naive CRPC. The company will only develop EC1169 in the taxanes-exposed CRPC population going forward and will discontinue EC1456, the analyst reported. He removed all sales from both drugs from his model ,citing uncertain initial results of 1169 in the taxane-exposed population. Target to $2 from $8.
06/05/17
COWN
06/05/17
DOWNGRADE
COWN
Market Perform
Endocyte downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Boris Peaker downgraded Endocyte to Market Perform from Outperform due to the failure of its lead asset, EC1456, and higher uncertainty with its pipeline.
PGNX Progenics
$5.52

-0.07 (-1.25%)

07/12/17
CANT
07/12/17
INITIATION
Target $15
CANT
Overweight
Progenics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Mara Goldstein started Progenics Pharmaceuticals with an Overweight rating and $15 price target. The analyst views the expectations of both the company's clinical and commercial success as modest.
04/24/17
NEED
04/24/17
NO CHANGE
Target $14
NEED
Strong Buy
Needham remains a buyer of Progenics after recent pullback
Needham analyst Chad Messer notes that Progenics' shares have pulled back since the reporting of controversial pivotal Azedra data a few weeks ago, but he is quite optimistic about Azedra's chances for approval and commercial success. The analyst says he remains a buyer of Progenics, reiterating a Strong Buy rating and $14 price target on the shares.
02/06/17
02/06/17
UPGRADE
Target $14

Strong Buy
Progenics upgraded to Strong Buy at Needham
As previously reported, Needham analyst Chad Messer upgraded Progenics to Strong Buy from Buy ahead of pivotal Azdedra data, and potential late 2017 launch. The analyst continues to expect "significant appreciation" in shares this year as the company launches its first wholly owned product and moves rapidly toward profitability. He also raised his price target on the shares to $14 from $11.
02/06/17
NEED
02/06/17
UPGRADE
NEED
Strong Buy
Progenics upgraded to Strong Buy from Buy at Needham

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

13:17
04/23/18
04/23
13:17
04/23/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
04/23/18
04/23
13:16
04/23/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$225.89

-2.85 (-1.25%)

, GOOG

Alphabet

$1,073.74

1.01 (0.09%)

13:15
04/23/18
04/23
13:15
04/23/18
13:15
Hot Stocks
Social Capital's Palihapitiya names Box as 2018 Sohn pick »

Sees artificial…

NVDA

Nvidia

$225.89

-2.85 (-1.25%)

GOOG

Alphabet

$1,073.74

1.01 (0.09%)

GOOGL

Alphabet Class A

$1,079.06

2.42 (0.22%)

AMZN

Amazon.com

$1,528.99

1.6 (0.10%)

BOX

Box

$20.48

-0.18 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 26

    Apr

  • 10

    May

BOX

Box

$20.47

-0.19 (-0.92%)

13:14
04/23/18
04/23
13:14
04/23/18
13:14
Hot Stocks
Breaking Hot Stocks news story on Box »

Box jumps 8% as Chamath…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$14.28

0.025 (0.18%)

13:14
04/23/18
04/23
13:14
04/23/18
13:14
Periodicals
Breaking Periodicals news story on Deutsche Bank »

Deutsche Bank weighs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

BPMP

BP Midstream

$18.84

0.55 (3.01%)

, BP

BP

$43.65

0.145 (0.33%)

13:13
04/23/18
04/23
13:13
04/23/18
13:13
Periodicals
BP Midstream holders may sell 10M more units starting Tuesday, Bloomberg says »

Large BP Midstream…

BPMP

BP Midstream

$18.84

0.55 (3.01%)

BP

BP

$43.65

0.145 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

RYCEY

Rolls-Royce

13:10
04/23/18
04/23
13:10
04/23/18
13:10
Periodicals
Rolls-Royce weighs China JV for new wide-body aircraft, Bloomberg says »

Rolls-Royce is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBT

BB&T

$53.38

0.66 (1.25%)

13:10
04/23/18
04/23
13:10
04/23/18
13:10
Options
Bullish option play opened in BB&T »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

DHI

D.R. Horton

$43.36

0.34 (0.79%)

13:00
04/23/18
04/23
13:00
04/23/18
13:00
Options
DR Horton draws far upside call writing ahead of earnings »

DR Horton draws far…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FB

Facebook

$167.80

1.51 (0.91%)

12:58
04/23/18
04/23
12:58
04/23/18
12:58
Hot Stocks
DoubleLine's Gundlach says go short Facebook »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

XOP

SPDR Oil Exploration and Production Fund

$38.82

-0.06 (-0.15%)

12:58
04/23/18
04/23
12:58
04/23/18
12:58
Hot Stocks
DoubleLine's Gundlach says go long SPDR Oil Exploration and Production Fund »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APDN

Applied DNA Sciences

12:56
04/23/18
04/23
12:56
04/23/18
12:56
Initiation
Applied DNA Sciences initiated  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

FB

Facebook

$167.77

1.48 (0.89%)

12:55
04/23/18
04/23
12:55
04/23/18
12:55
Hot Stocks
DoubleLine's Gundlach calls apology by Facebook's Zuckerberg 'disingenuous' »

Jeffrey Gundlach, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

WPG

Washington Prime

12:50
04/23/18
04/23
12:50
04/23/18
12:50
Options
Washington Prime with notable put buying ahead of earnings »

Washington Prime with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

AAPL

Apple

$165.70

-0.01 (-0.01%)

12:48
04/23/18
04/23
12:48
04/23/18
12:48
Hot Stocks
CIRP: iPhone X demand slows as iPhone 8, 8 Plus mix climbs in March quarter »

Consumer Intelligence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

OAS

Oasis Petroleum

$10.16

0.01 (0.10%)

12:45
04/23/18
04/23
12:45
04/23/18
12:45
Options
Oasis Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

ASND

Ascendis Pharma

$63.01

-0.82 (-1.28%)

12:45
04/23/18
04/23
12:45
04/23/18
12:45
Conference/Events
Ascendis Pharma has a conference call hosted by JPMorgan »

JPMorgan Analyst Fye will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 08

    May

  • 10

    May

CNSL

Consolidated Communications

$10.94

-0.04 (-0.36%)

12:41
04/23/18
04/23
12:41
04/23/18
12:41
Hot Stocks
Consolidated Communications launches DDoS mitigation solution »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$68.72

0.31 (0.45%)

, LLY

Eli Lilly

$79.47

0.38 (0.48%)

12:36
04/23/18
04/23
12:36
04/23/18
12:36
Recommendations
Incyte, Eli Lilly analyst commentary  »

Incyte AdCom meeting…

INCY

Incyte

$68.72

0.31 (0.45%)

LLY

Eli Lilly

$79.47

0.38 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 07

    May

  • 21

    May

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

GRUB

GrubHub

$103.01

1.32 (1.30%)

12:35
04/23/18
04/23
12:35
04/23/18
12:35
Hot Stocks
Half Sky's Ran says GrubHub has 'significant room for growth' »

Says young people are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 29

    May

  • 12

    Jun

GRUB

GrubHub

$103.59

1.9 (1.87%)

12:30
04/23/18
04/23
12:30
04/23/18
12:30
Hot Stocks
Half Sky's Ran says GrubHub is "attractive investment idea" »

Li Ran, CIO, Half Sky…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 29

    May

  • 12

    Jun

LITE

Lumentum

$57.25

-1.65 (-2.80%)

12:27
04/23/18
04/23
12:27
04/23/18
12:27
Hot Stocks
Lumentum falls to session lows, down 5% »

Shares of Lumentum have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

DHI

D.R. Horton

$43.22

0.2 (0.46%)

12:26
04/23/18
04/23
12:26
04/23/18
12:26
Hot Stocks
Long Pond's Khoury sees D.R. Horton at $71.50 per share »

Says incredibly strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

12:25
04/23/18
04/23
12:25
04/23/18
12:25
General news
NABE Business Conditions Survey showed strong sales expectations »

NABE Business Conditions…

12:25
04/23/18
04/23
12:25
04/23/18
12:25
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss dental…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.